A novel isocarpone derivative derived from Japanese snakeroot, and its preparation method and application

By extracting and isolatinoid derivatives from Japanese snake root grass, the problem of toxic side effects of existing uric acid-lowering drugs is solved, effective inhibition of xanthine oxidase is achieved, and a safe and efficient new type of reducing the disease is provided. Uric acid drugs are superior to existing drugs and pass through a green and environmentally friendly production process.

CN114409715BActive Publication Date: 2024-11-15SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210074390.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-21
Publication Date
2024-11-15
Estimated Expiration
2042-01-21

AI Technical Summary

Technical Problem

Existing uric acid-lowering drugs such as allopurinol and febuxostat have toxic side effects, which makes it still a research task to find safe and efficient new uric acid-lowering drugs, and there are few researches on the chemical composition of plants of the genus Snake Root, especially isolaminophen. There are few studies on the activity of alkaloids.

Method used

A isolaminoid derivative was extracted and isolated from Japanese snake root grass, and it was dried and crushed, extracted by methanol aqueous solution, acid-base treatment, macroporous resin column chromatography, reverse phase column chromatography, and gel column chromatography through drying and pulverizing, leaching aqueous methanol solution, acid-base treatment, macroporous resin column chromatography, reverse phase column chromatography, and gel column chromatography Purification was obtained by high-performance liquid chromatography and other steps to obtain a compound with xanthine oxidase inhibitory activity, which was used to prepare a new uric acid-lowering drug.

Benefits of technology

This isolaminophen derivative significantly inhibits xanthine oxidase activity, reduces uric acid production, is better than the existing gout drug allopurinol, has potential new uric acid-lowering drug use, and passes through a green and environmentally friendly production process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003483400580000021
    Figure BDA0003483400580000021
  • Figure BDA0003483400580000051
    Figure BDA0003483400580000051
  • Figure BDA0003483400580000061
    Figure BDA0003483400580000061
Patent Text Reader

Abstract

The present invention relates to the technical field of medicine and chemistry, and specifically discloses a kind of Ophiorrhiza japonica ) iso-rutin derivatives and their preparation methods and use in the preparation of drugs with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory effect of the iso-rutin derivatives of the present invention is better than that of allopurinol, a widely used uric acid-lowering drug in clinical practice, and is a highly effective xanthine oxidase inhibitor that can be used to prepare new drugs for gout.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medicine and chemistry, and in particular to an isocarpone derivative derived from Ophiorrhiza japonica, a preparation method thereof, and an application of the isocarpone derivative in the preparation of a drug having xanthine oxidase inhibitory activity. Background Art

[0002] With the changes in modern living habits and dietary structure, the incidence of hyperuricemia has increased. Hyperuricemia is an increase in the production of uric acid in the body and a decrease in the excretion of uric acid in the kidneys, which makes the uric acid concentration in the body higher than the blood's solubility capacity (>360μmol / L). Uric acid is deposited in the joints in the form of crystals, and repeated attacks lead to gouty arthritis and uric acid kidney stones. These deposited crystals cause repeated inflammatory and severe pain in soft tissues, joints, and bone tissues, seriously reducing the patient's quality of life.

[0003] The treatment of hyperuricemia requires lowering the blood uric acid concentration in the body. Xanthine oxidase (XOD) is an important target, which is mainly distributed in the liver and intestines and oxidizes hypoxanthine and xanthine into uric acid in the purine metabolic pathway. Therefore, inhibiting XOD activity can reduce uric acid production. Currently, uric acid-lowering drugs that inhibit XOD can be divided into purine and non-purine types. Allopurinol is the most commonly used clinical XOD purine inhibitor, but it is controversial due to its toxic side effects such as Stevens-Johnson syndrome and nephrotoxicity. Febuxostat, as a non-purine XOD inhibitor, can also cause cardiovascular complications, and the Food and Drug Administration (FDA) also needs to supplement the warning statement of the drug. Therefore, finding new uric acid-lowering drugs with high safety and strong effects remains a research task for pharmacists.

[0004] Ophiorrhiza belongs to the Rubiaceae family and is a perennial herb. There are about 200 species in the world, and about 70 species in my country. According to the Hunan Pharmacopoeia, it has the effects of promoting blood circulation, regulating menstruation and relieving pain, and relieving cough. It is mainly used for rheumatic pain, cough, cold limbs and abdominal pain, dysmenorrhea, and injury. Although there are many species of plants in this genus, there are few reports on the chemical composition, which mainly includes steroids, anthraquinones, terpenes and alkaloids. Isocaryophyllene alkaloids are the key biosynthetic precursors of more than 2,000 monoterpene indole alkaloids. Monoterpene indole alkaloids converted from isocaryophyllene have a wide range of biological activities, and some have become commonly used clinical drugs, such as reserpine for antihypertension, amarin for antiarrhythmia, camptothecin for antitumor, vinblastine and vincristine for anticancer, quinine for antimalarial, and adrenergic receptor blocker yohimbine. However, as a key precursor of biosynthesis, there are few reports on the activity of isocarpioside alkaloids, and only some compounds have been published on the activity of inhibiting immune cells and acetylcholinesterase. This application is the first to discover that isocarpioside alkaloids have the activity of inhibiting xanthine oxidase. Summary of the invention

[0005] In view of the deficiencies in the prior art, the object of the present invention is to provide an iso-scabiosin derivative derived from Japanese snakeroot, a preparation method thereof, and an application thereof in the preparation of a drug having xanthine oxidase inhibitory activity.

[0006] An isocarpone derivative having xanthine oxidase inhibitory activity, the structural formula of which is as follows:

[0007]

[0008] Molecular formula: C 26 H 26 N2O 10 .

[0009] The preparation method of the above-mentioned isothiocyanate derivatives with xanthine oxidase inhibitory activity comprises the following steps: taking the whole herb of Japanese snakeroot (Ophiorrhiza japonica), drying and crushing it, and then extracting it with 80% (v / v) methanol aqueous solution for 2-5 times; the water-soluble parts of the extract are separated and purified by acid-base treatment, macroporous resin column chromatography, reverse phase column chromatography, gel column chromatography, silica gel column chromatography and high performance liquid chromatography to obtain a new compound.

[0010] The use of the isobutyrosin derivatives in the preparation of drugs having xanthine oxidase inhibitory activity also falls within the protection scope of the present invention.

[0011] Another object of the present invention is to provide an isobutyrosin derivative for use in preparing a drug for inhibiting uric acid synthesis for gouty arthritis.

[0012] In the present invention, all of the above xanthine oxidase inhibitory activities are specifically embodied in that the xanthine oxidase can significantly reduce the oxidation of xanthine to uric acid, and the inhibitory effect is better than that of the positive control drug allopurinol.

[0013] The experiments of the present invention prove that the isobutyrosin derivatives show obvious inhibitory effect on xanthine oxidase in the experiment of inhibiting uric acid production, and have potential use as a preparation of new uric acid-lowering drugs.

[0014] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0015] 1. The present invention discloses for the first time an iso-scutellarin derivative isolated from Snakeroot plants, which has xanthine oxidase inhibitory activity. In the future, the scientific community will focus on finding lead compounds with xanthine oxidase inhibitory activity from Snakeroot plants.

[0016] 2. The present invention provides an isobutyric acid-lowering activity-containing isobutyric acid derivative, which has a better inhibitory effect on xanthine oxidase than allopurinol, a widely used gout drug in clinic. It is a highly effective xanthine oxidase inhibitor and can be used to prepare a new type of uric acid-lowering drug.

[0017] 3. The isocarpone derivatives of the present invention can be obtained by extraction and purification from plants. The entire production process is chemical-free and environmentally friendly. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This is the hydrogen spectrum (600 MHz, MeOD) of the compound prepared in Example 1 in the specific implementation manner;

[0019] Figure 2 The carbon spectrum (150 MHz, MeOD) and DEPT diagram of the compound prepared in Example 1 in the specific implementation manner;

[0020] Figure 3 It is the HMQC diagram of the compound prepared in Example 1 in the specific embodiment;

[0021] Figure 4 It is the HMBC diagram of the compound prepared in Example 1 in the specific implementation mode;

[0022] Figure 5 The compound prepared in Example 1 in the specific embodiment 1 H- 1 H COSY diagram;

[0023] Figure 6ROESY diagram of the compound prepared in Example 1 in the specific embodiment;

[0024] Figure 7 It is a liquid chromatogram of the compound prepared in Example 1 in the specific implementation manner. DETAILED DESCRIPTION

[0025] In order to make the invention purpose and invention content of this application more clearly presented, the applicant will provide a clear and complete description of the technical solution of the present invention in conjunction with specific embodiments below.

[0026] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0027] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0028] Example 1: The compound described in the claims and the invention description - an isocarptoside derivative is obtained as follows:

[0029] The separation and purification process of the compound: the whole plant of freshly picked Japanese snakeroot (Ophiorrhiza japonica) is dried, 10 kg of the dried whole plant of Japanese snakeroot (Ophiorrhiza japonica) is taken, crushed and soaked in 80% (v / v) methanol aqueous solution for 3 times (3×20L), each time for 2 days, the 3 extracts are combined, concentrated under reduced pressure, and methanol is recovered to obtain a total extract. The total extract is completely dissolved with 0.5wt% HCl solution, the pH is adjusted to 2-3 with 1.85wt% HCl solution, and extracted with an equal volume of ethyl acetate for 3 times; the acid water part is adjusted to pH 8-9 with 2.8wt% ammonia water, and then extracted with an equal volume of ethyl acetate for 3 times. The remaining alkaline water layer is subjected to column chromatography with 5 kg of macroporous resin (D101). First, the pretreated macroporous resin is filled into a glass chromatography column by wet column loading to ensure uniformity and no bubbles. Use distilled water to press the column until the column height remains unchanged, then stop adding liquid; when the liquid level drops to about 5mm above the column surface, close the liquid outlet. Carefully add the water layer sample slowly along the wall of the chromatography column, open the liquid outlet, control the liquid outlet rate, and avoid the liquid level from dropping too quickly. After all samples are added to the chromatography column, when the liquid level drops to about 5mm above the column surface, rinse the column wall with a small amount of distilled water, repeat 2-3 times until the liquid on the column surface is clear and colorless, slowly fill the chromatography column with distilled water, close the liquid outlet at the same time, and let it stand overnight (12h) until adsorption equilibrium is reached. Use 50L of 0%, 20%, 40%, 80% and 100% ethanol aqueous solution (v / v) step by step, with a flow rate of 100mL / min. The components were concentrated under reduced pressure at 50°C to obtain 450 g of 0% ethanol aqueous solution (v / v) component extract, 113 g of 20% ethanol aqueous solution (v / v) component extract, 34 g of 40% ethanol aqueous solution (v / v) component extract, 20 g of 80% ethanol aqueous solution (v / v) component extract, and 67 g of 100% ethanol aqueous solution (v / v) component extract. To a 20% ethanol aqueous solution (v / v) component extract (113 g), an appropriate amount of methanol was added as a solvent to dissolve and transferred to an evaporating dish, 120 g of reversed-phase silica gel (Fuji Silysia Chemical Co., Ltd., Japan, Lichroprep RP-18, 40-70 μm) was added to adsorb the sample, and the sample was allowed to stand in a fume hood for air drying and ground into powder. Then, medium-pressure chromatography (Biotage, Sweden, C-615 pump manager, C-605 pump module, C-660 fraction collector, RP-18 chromatographic column) was used, and gradient elution was performed with methanol-water (0:100, 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10, 100:0, v / v) as the eluent, at a flow rate of 35 mL / min, and 10 L of each ratio was eluted and concentrated and recovered.Detect by silica gel thin layer chromatography, develop with chloroform-methanol (1:1, v / v) as developing agent, develop with potassium bismuth iodide, combine the components with the same or similar Rf values, and finally combine them into 8 components, which are numbered in alphabetical order from A to H in the order of elution. Take the eluted C component (15.5g, which is the elution ratio of 20:80 (v / v) methanol-water in medium pressure chromatography, and the elution volume is the 5th to 10th L of the ratio) and isocratically elute with 60% (v / v) methanol aqueous solution through Sephadex LH-20 gel at a flow rate of 10mL / min, and fill one bottle for every 20mL, detect by silica gel thin layer chromatography, develop with chloroform-methanol (1:1, v / v) as developing agent, and develop with potassium bismuth iodide, concentrate and combine the components with the same or similar Rf values, and finally combine them into 6 components, which are numbered in order from C1 to C6 in the order of elution. The eluted component C2 (50-110 min, 2.6 g) was taken and subjected to normal phase silica gel column chromatography (Qingdao Ocean Chemical Co., Ltd., thin layer chromatography silica gel, 200-300 mesh, chloroform-methanol, 4:1, 2:1, 1:1, 0:1, v / v) gradient elution at a flow rate of 5 mL / min. 300 mL of solution was eluted at each ratio, and detected by silica gel thin layer chromatography, chloroform-methanol (1:1, v / v) developing agent, and potassium bismuth iodide color development. The components with the same or similar Rf values ​​were concentrated and combined to obtain 6 components, which were numbered in sequence from C2-1 to C2-6 in the order of elution. The eluted component C2-2 (270 mg, elution ratio of chloroform-methanol in normal phase silica gel column chromatography is 2:1 (v / v), and the elution volume is the combination of the 120 ml to the 300 ml of this ratio) was subjected to high performance liquid chromatography (column: Agilent Zorbax SB-C18 column, specification: 9.4 mm×150 mm; acetonitrile-water gradient elution, 5%-20%, v / v; 4 mL / min) (the liquid chromatogram of this step is shown. Figure 7 ), vacuum concentrated and dried to prepare the compound 1 of the present invention (light yellow powder, 10.4 mg, t R =21.5min).

[0030] Structural identification of the compound: The powdered compound prepared in Example 1 was dissolved in 0.5 mL of deuterated methanol, transferred to an NMR tube using a 200 μL pipette, and the hydrogen spectrum, carbon spectrum, and two-dimensional spectrum (such as Figure 1-6 ).

[0031] The NMR data of the obtained isocarptoside derivatives:

[0032]

[0033]

[0034] Other physical and chemical data of isobutyric acid derivatives:

[0035] Appearance: light yellow powder; specific rotation UV(MeOH)λ max (log ε ):220(2.95),285(2.95),350(2.62)nm; High resolution mass spectrometry HR-ESI-MS m / z 527.1660[M+H] + (calcdfor C 26 H 27 N2O 10 :527.1656).

[0036] According to the results of the above tests, the structural formula of the obtained compound is confirmed to be as follows:

[0037]

[0038] Molecular formula: C 26 H 26 N2O 10 .

[0039] Example 2: Xanthine oxidase inhibitory activity

[0040] Principle: Add different mass concentrations of raw materials, xanthine and xanthine oxidase into the reaction system. Under the catalysis of xanthine oxidase, the substrate xanthine is oxidized into uric acid. Uric acid has a characteristic absorption peak at 295nm. The effect of the raw materials on the in vitro activity of xanthine oxidase is determined by measuring the generation rate of the reaction product uric acid, and the IC is calculated. 50 value.

[0041] 1. Solution preparation:

[0042] Phosphate Buffered Saline:

[0043] Take 14.87 g of K2HPO4, 1.99 g of KH2PO4, and 0.1861 g of EDTA-2Na (disodium ethylenediaminetetraacetate), dissolve them in 500 ml of water to prepare 0.2 mol / L phosphate buffer (pH 7.5).

[0044] Xanthine solution (substrate):

[0045] Weigh 1 mg of xanthine and dissolve it in 1 mL of DMSO (dimethyl sulfoxide) to obtain a 1 mg / mL mother solution. When using, take 400 μL of the mother solution and add 6174 μL of 0.2 mol / L phosphate buffer (pH 7.5) to obtain a 400 μmol / L xanthine application solution.

[0046] Xanthine oxidase solution:

[0047] Divide the xanthine oxidase containing 5U into 5 equal parts, accurately add 1mL of triple-distilled water to the xanthine oxidase containing 1U, mix the xanthine oxidase solution thoroughly and dispense it into 20 1mL EP tubes, continue to freeze and store at -20℃, and only need to dissolve the required amount of enzyme (2.5U / L) each time.

[0048] Sample and reference solution:

[0049] Sample (Compound C prepared in Example 1 26 H 26 N2O 10 ):

[0050] The test compounds were dissolved in DMSO (dimethyl sulfoxide) with a stock solution concentration of 2 mmol / L. The test compound was diluted to 100 μmol / L as the highest concentration, and then diluted to 2 times with 10 concentrations: 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, 0.195 μmol / L.

[0051] Allopurinol:

[0052] Allopurinol was dissolved in DMSO, and the stock solution concentration was 10 mmol / L. The highest concentration of the test control substance was 100 μmol / L, and the test control substance was diluted 2-fold to 10 concentrations: 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, 0.195 μmol / L.

[0053] 2. Experimental process:

[0054] Determination of measurement wavelength:

[0055] Use a UV-visible spectrophotometer to perform spectrum scanning at 200-400 nm. Obtain the characteristic absorption wavelength of uric acid based on the spectrum scanning curve. Select the measurement wavelength as 295 nm.

[0056] Sample determination:

[0057] 100 μL 0.2 mol / L phosphate buffer (pH 7.5) was added to the blank control group; 60 μL 0.2 mol / L phosphate buffer (pH 7.5) was first added to the negative control group; 20 μL 0.2 mol / L phosphate buffer (pH 7.5) and 40 μL xanthine oxidase solution (hereinafter referred to as "enzyme solution", 2.5 U / L) were added to the enzyme group; 20 μL sample solution of different concentrations and 40 μL enzyme solution (2.5 U / L) were added to the sample determination group; 20 μL sample solution of different concentrations and 40 μL 0.2 mol / L phosphate buffer (pH 7.5) were added to the sample negative control group; 20 μL allopurinol solution of different concentrations and 40 μL enzyme solution (2.5 U / L) were added to the allopurinol determination group; 20 μL allopurinol solution of different concentrations and 40 μL 0.2 mol / L phosphate buffer (pH 7.5) were added to the allopurinol negative control group. After the sample addition, it was placed in a constant temperature box and incubated at 25°C for 15 minutes. After the incubation, 40 μL of xanthine solution (400 μmol / L) was added to all except the blank control group, and the final volume of each group was 0.1 mL, and the kinetic method was immediately measured at a wavelength of 295 nm, with a reading time of 30 minutes, 1 minute / time.

[0058] 3. Calculation of inhibition rate

[0059] Xanthine oxidase inhibition rate calculation formula:

[0060] IC 50 IC refers to the concentration of the compound when the enzyme activity inhibition rate is 50%. 50 The calculation software used was GraphPad Prism 5.

[0061] 4. Experimental Results

[0062] After in vitro activity testing, the isobutyrosin derivative C 26 H 26 N2O 10 It has significant inhibitory activity against xanthine oxidase, with an IC 50 The positive control drug allopurinol (IC 50 =11.1μmol / L)10-15 times.

Claims

1. An isocarptoside derivative, characterized in that: Its structural formula is:

2. Use of the isobutyrosin derivatives according to claim 1 in the preparation of drugs for inhibiting xanthine oxidase.

3. Use of the isobutyrosin derivatives according to claim 1 in the preparation of uric acid-lowering drugs.

4. Use of the isobutyrosin derivatives according to claim 1 in the preparation of a drug for inhibiting uric acid synthesis for gouty arthritis.